Patients with previously treated metastatic pancreatic ductal adenocarcinoma can now receive daraxonrasib, an investigational drug from Revolution Medicines, outside of a clinical trial after the FDA cleared an expanded access protocol just two days after the company’s request. The speed of the agency’s action and the company’s stated intent to file a New Drug Application under a special expedited review program signal that a formal approval decision could arrive faster than the typical regulatory timeline for oncology drugs.
Why expanded access to daraxonrasib matters right now
Pancreatic cancer kills most patients within a year of diagnosis, and second-line treatment options have historically offered only modest survival gains. The FDA’s decision to issue a safe to proceed letter for daraxonrasib creates an immediate path for patients who cannot enroll in the ongoing Phase 3 trial but whose disease has progressed on prior therapy. For those patients, the expanded access treatment protocol is not a bureaucratic abstraction. It is the difference between receiving an active drug and waiting months for a regulatory decision that has not yet been filed.
The two-day turnaround between Revolution Medicines’ request and the FDA’s clearance is unusually fast, even by expanded access standards. That pace reflects the strength of the clinical data package behind daraxonrasib, a RAS(ON) multi-selective inhibitor designed to block mutant RAS proteins that drive the majority of pancreatic cancers. The drug’s mechanism targets a biology that has resisted effective treatment for decades, which partly explains the agency’s willingness to act quickly.
A separate but related development adds urgency. Revolution Medicines disclosed in an SEC filing that it intends to submit Phase 3 data to the FDA as part of a future New Drug Application under the Commissioner’s National Priority Voucher program. That program is designed to shorten FDA review timeframes for drugs the agency deems aligned with national health priorities. If the NDA submission follows the timeline the company’s disclosure implies, a formal approval decision could come well before the standard review clock would normally expire.
Phase 3 results and the RASolute 302 trial
The clinical foundation for expanded access rests on two published studies. The pivotal evidence comes from Phase 3 data from RASolute 302, a randomized trial registered on ClinicalTrials.gov as NCT06625320, which compared daraxonrasib against investigator’s choice standard-of-care chemotherapy in patients with previously treated metastatic pancreatic cancer. Results published in the New England Journal of Medicine provided the efficacy and safety data that both the FDA and Revolution Medicines have cited as the basis for moving toward approval.
In RASolute 302, patients had disease that had already progressed on first-line regimens, leaving few effective options. The trial evaluated clinically meaningful endpoints such as progression-free survival, overall survival, and objective response rate, along with quality-of-life measures. Daraxonrasib showed a statistically significant benefit over chemotherapy on key outcomes, with a tolerability profile that allowed many patients to remain on therapy longer than is typical with cytotoxic regimens. Those findings underpinned the argument that withholding the drug until full approval would be difficult to justify for patients lacking alternatives.
Earlier-stage data from the Phase 1–2 trial RMC-6236-001, registered as NCT05379985 and also published in the New England Journal of Medicine, established the drug’s safety profile and showed durable responses in RAS-mutated pancreatic cancer. That study provided the mechanistic rationale for daraxonrasib as a RAS(ON) multi-selective inhibitor, a class of drug that binds to active, GTP-bound forms of multiple RAS variants rather than targeting a single mutation. The ability to inhibit several oncogenic RAS isoforms simultaneously is particularly relevant in pancreatic ductal adenocarcinoma, where KRAS mutations are nearly ubiquitous but not uniform, and resistance pathways can emerge through signaling redundancy.
Importantly, the early-phase trial characterized dose-limiting toxicities, common adverse events, and pharmacokinetic parameters, allowing optimization of the dose used in RASolute 302. Together, the Phase 1–2 and Phase 3 datasets formed a coherent story: a first-in-class RAS(ON) inhibitor with a manageable safety profile and clear efficacy signals in a population that has historically seen only incremental gains.
Whether the CNPV pilot can speed RAS-targeted drug reviews
The Commissioner’s National Priority Voucher pilot program is still new, and daraxonrasib is among the first oncology drugs to be publicly linked to it. The CNPV initiative was created to shorten FDA review timeframes for applications the agency identifies as serving national interests. Whether it will compress NDA review times for RAS-targeted agents by a significant margin compared with historical medians is a question that can only be answered after the first batch of applications moves through the process.
The hypothesis that the CNPV pilot could cut review times by 40 percent or more is plausible in theory but unverifiable today. Standard FDA review for new oncology drugs has often taken close to a year under priority review and longer under standard review. The CNPV program’s stated goal is to shorten those windows, but the agency has not published specific target timelines or committed to a defined percentage reduction. Future FDA approval-date databases will eventually show whether the program delivers on its promise, but for now the mechanism exists only as a framework, not a track record.
What is concrete is the sequence of events already in motion. The FDA cleared expanded access. Revolution Medicines has stated its intent to file an NDA. The CNPV designation suggests the agency views the application as aligned with broader public health priorities, potentially positioning daraxonrasib for a faster-than-usual review once the submission is complete.
What expanded access means for patients and clinicians
For patients, expanded access offers a structured route to receive daraxonrasib outside a randomized trial. Eligibility criteria typically mirror those of the pivotal study but allow for some flexibility, such as accommodating patients who live far from trial sites or who have comorbidities that would have excluded them from RASolute 302. Treating physicians must still navigate institutional review board oversight and informed consent, but the FDA’s rapid clearance removes a major regulatory barrier.
Clinicians now face practical decisions about when to seek expanded access versus steering patients toward ongoing studies. For individuals who qualify for RASolute 302 or other controlled trials, participation in research remains important for generating robust comparative data. However, for patients who fall just outside trial parameters yet remain fit enough for systemic therapy, expanded access to daraxonrasib may represent the most rational option, given the strength of the existing evidence and the limited efficacy of third-line chemotherapy.
Health systems will also need to consider logistics, including drug acquisition, monitoring requirements, and documentation of outcomes. Although expanded access programs are not designed as research studies, real-world experience with daraxonrasib in broader practice settings could inform future safety updates, dosing recommendations, and combination strategies. That information will be particularly valuable if the drug moves rapidly from investigational status to full approval under an accelerated review clock.
Looking ahead to potential approval
The convergence of strong clinical data, rapid expanded access clearance, and participation in the CNPV pilot places daraxonrasib on an unusually fast regulatory trajectory for a pancreatic cancer therapy. The ultimate timeline will depend on when Revolution Medicines submits its NDA, how efficiently the company responds to FDA information requests, and whether any new safety signals emerge as more patients receive the drug under expanded access.
Even with those uncertainties, the current path marks a notable shift in how regulators and developers are approaching RAS-driven pancreatic cancer. For a disease long defined by therapeutic stagnation, the prospect of a first-in-class RAS(ON) inhibitor moving swiftly through review is more than a symbolic milestone. It represents a concrete, near-term opportunity to change the treatment landscape for patients who have had few reasons for optimism.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
